Scholarlink

<p>Variation in the gene for apolipoprotein E (<i>APOE</i>) is one of the few variables that is associated with individual differences in age-related cognitive decline in humans. Therefore, it is important to understand the conditions that affect the strength of its effect. Here we examine how the effect size of <i>APOE</i> variation (possession of one or more e4 alleles) on a test of general cognitive ability changes with age from 11–90 years. The data are from the Lothian Birth Cohorts of 1936 and 1921 who took the same cognitive test (the Moray House Test No. 12) at, respectively, ages 11 (N = 954), 70 (N = 1001), 76 (N = 636), 79 (N = 471), and 11 (N = 483), 79 (N = 533), 87 (N = 198), 90 (N = 120). The standardised absolute effect of <i>APOE</i> e4 on general cognitive ability was about zero at ages 11 (beta &lt; 0.05) and 70 (beta ≤ 0.025) and increased linearly to beta = 0.30 (p &lt; 0.001) at age 90. The effect sizes were minimally affected by adjusting for medical conditions (hypertension, diabetes, cardiovascular disease, stroke). However, the results were less robust to removing those participants who developed dementia; effect sizes were reduced by about a third to a half, and were largely non-significant. The results suggest that the negative effect of <i>APOE</i> e4 on cognitive functioning becomes greater with age; this urges more work to understand the mechanisms by which e4 status renders the older person’s brain increasingly vulnerable to cognitive decline and dementia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect sizes of APOE e4 on the same general cognitive ability test taken by the same people from age 11 to age 90: The Lothian Birth Cohorts 1921 and 1936

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月6日

查看全文
  • Ian J. Deary,
  • Sarah E. Harris,
  • Tom C. Russ,
  • Simon R. Cox,
  • Janie Corley

摘要

Variation in the gene for apolipoprotein E (APOE) is one of the few variables that is associated with individual differences in age-related cognitive decline in humans. Therefore, it is important to understand the conditions that affect the strength of its effect. Here we examine how the effect size of APOE variation (possession of one or more e4 alleles) on a test of general cognitive ability changes with age from 11–90 years. The data are from the Lothian Birth Cohorts of 1936 and 1921 who took the same cognitive test (the Moray House Test No. 12) at, respectively, ages 11 (N = 954), 70 (N = 1001), 76 (N = 636), 79 (N = 471), and 11 (N = 483), 79 (N = 533), 87 (N = 198), 90 (N = 120). The standardised absolute effect of APOE e4 on general cognitive ability was about zero at ages 11 (beta < 0.05) and 70 (beta ≤ 0.025) and increased linearly to beta = 0.30 (p < 0.001) at age 90. The effect sizes were minimally affected by adjusting for medical conditions (hypertension, diabetes, cardiovascular disease, stroke). However, the results were less robust to removing those participants who developed dementia; effect sizes were reduced by about a third to a half, and were largely non-significant. The results suggest that the negative effect of APOE e4 on cognitive functioning becomes greater with age; this urges more work to understand the mechanisms by which e4 status renders the older person’s brain increasingly vulnerable to cognitive decline and dementia.